Structure Therapeutics (NASDAQ:GPCR) (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development. These programs are directed at GPCR targets implicated in diseases such as nonalcoholic steatohepatitis (NASH), fibrosis and immune‐mediated inflammatory conditions. By applying structure‐guided optimization and high‐throughput screening, Structure Therapeutics aims to generate drug candidates with improved selectivity, potency and safety profiles compared with existing modalities.
Founded in 2018, the company initially operated under the name GPCR Therapeutics before rebranding as Structure Therapeutics in 2023 to reflect its emphasis on structure‐based drug design. Headquartered in Boston, Massachusetts, Structure Therapeutics collaborates with academic centers, contract research organizations and strategic partners to advance its research and development programs. Its integrated approach combines in silico modeling, biophysical assays and in vivo validation to streamline candidate progression toward human trials.
Led by a management team with extensive experience in drug discovery, translational research and clinical development, Structure Therapeutics aims to address areas of high unmet medical need. The company’s scientific leadership includes experts in GPCR biology, structural biology and pharmacology, positioning it to capitalize on breakthroughs in receptor structure elucidation and computational methods. Through its novel platform and focused pipeline, Structure Therapeutics seeks to bring first‐in‐class or best‐in‐class therapies to patients worldwide.
